AstraZeneca’s oncology immunotherapy Imfinzi (durvalumab) met the second primary endpoint of overall survival in the phase III trial for unresectable stage III non-small cell lung cancer (NSCLC).
Original Article: AstraZeneca’s Imfinzi extends survival rate in lung cancer patients